Today is #WearRedDay, and we gather in solidarity to raise awareness of cardiovascular disease—the leading cause of death for women. As we stand side by side, we shine a light on the importance of heart health for women. #HeartMonth #HeartDisease

$CYTK: We are looking forward to participating in the 35th Annual @Oppenheimer Healthcare Life Sciences Conference on February 11.

Some people with #HCM can go months or years without being diagnosed after their symptoms first start, and misdiagnosis is common. Thanh experienced small changes that made her limit her physical activity. Learn more about her story at #HCMBeyondtheHeart

We started AMBER-HFpEF, a Phase 2 clinical trial in patients with symptomatic heart failure with preserved ejection fraction. Read more:

At #JPM25, our CEO Robert Blum spoke with @BiotechTVHQ about the year ahead. Watch to hear more about our years-in-the-making story and how we hope to bring enduring value to shareholders and deliver on our mission for patients.

Each component of our Vision 2030 is designed to drive us toward becoming the leading muscle-focused specialty biopharma company. With innovation, equitable access, and global impact, we aim to deliver potential medicines and advance pioneering research to improve patient lives.

We unveiled Vision 2030, our strategic objectives designed to propel us into becoming the leading muscle-focused specialty biopharmaceutical company intent on meaningfully improving the lives of patients through global access to innovative medicines.

$CYTK: Cytokinetics President & CEO, Robert Blum will be speaking at the 43rd Annual @jpmorgan Healthcare Conference tomorrow at 9:00 AM. Watch the live webcast to hear about our plans for 2025 here: #JPM25

One of our top commitments as a corporate citizen is giving back to our local community, including funding programs that support STEM education. Listen to our President and CEO Robert Blum share his views on the importance of giving back and its impact.

$CYTK: We will be presenting at the 43rd Annual @jpmorgan Healthcare Conference. We’re going to share what's ahead for 2025 as we seek to meaningfully improve the lives of patients with diseases of impaired muscle function. #JPM25

Today we announced @sanofi acquired rights to develop and commercialize our investigational cardiac myosin inhibitor in Greater #China. Learn more: #HCM

We hosted our first-ever patient day – Polaris – where we invited #HCM patients and community members for a day filled with activities, discussions, connection, and purpose. It was a meaningful and emotional day that affirmed our commitment to the #patient journey and community.

We are pleased to be starting COMET-HF, a confirmatory Phase 3 clinical trial for patients with symptomatic heart failure (HF) with severely reduced ejection fraction. Read more: #HeartFailure #CardioTwitter

$CYTK Today we announced that we will participate in upcoming investor conferences hosted by @EvercoreISI and @Piper_Sandler.

We’re excited to share that the @US_FDA has accepted our New Drug Application for our potential next-in-class cardiac myosin inhibitor in adult patients with obstructive hypertrophic cardiomyopathy (HCM). Learn more here: #HCM #CardioTwitter

Today we announced an exclusive licensing collaboration with @Bayer for the development and commercialization of our investigational cardiac myosin in Japan for the treatment of patients with obstructive and non-obstructive #HCM. #CardioTwitter

We announced additional data related to our investigational cardiac myosin activator presented at #AHA24. Learn more here: #HeartFailure

Today is our industry theater presentation at #AHA24, “Navigating the Complexities of Hypertrophic Cardiomyopathy: Addressing Delayed Diagnosis, Disease Burden, and Shared Decision-Making.” Learn more here: #HCM #CardioTwitter

Today we announced new data related to our investigational cardiac myosin inhibitor presented at #AHA24. Learn more here: #HCM #CardioTwitter

Don’t miss our VP of Medical Affairs, Richey Neuman, MD, MPH, FACP at the Biotechnology Industry Showcase at @ucsantabarbara. As a panelist, Richey will be one of the voices to speak about the biotech industry. Learn more here: